" /> Alagille syndrome 1 - CISMeF





Preferred Label : Alagille syndrome 1;

Symbol : ALGS1;

CISMeF acronym : AHD; ALGS; ALGS1; AWS;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : Alagille-watson syndrome; Cholestasis with peripheral pulmonary stenosis; Hepatic ductular hypoplasia, syndromatic; Arteriohepatic dysplasia; AWS; AHD; ALGS; Alagille syndrome;

Description : Alagille syndrome is an autosomal dominant disorder that traditionally has been defined by a paucity of intrahepatic bile ducts, in association with 5 main clinical abnormalities: cholestasis, cardiac disease, skeletal abnormalities, ocular abnormalities, and a characteristic facial phenotype (Li et al., 1997). Cholestasis is a direct consequence of the paucity of bile ducts. About 39% of patients also have renal involvement, mainly renal dysplasia (Kamath et al., 2012). Turnpenny and Ellard (2012) reviewed the clinical features, diagnosis, pathogenesis, and genetics of Alagille syndrome. - Genetic Heterogeneity of Alagille Syndrome Another form of Alagille syndrome (ALGS2; 610205) is caused by mutation in the NOTCH2 gene (600275).;

Inheritance : Autosomal dominant;

Molecular basis : Caused by mutation in the jagged 1 gene (JAG1, 601920.0001);

Neoplasia : Hepatocellular carcinoma; Papillary thyroid carcinoma;

Laboratory abnormalities : Increased conjugated bilirubin; Hypercholesterolemia; Hypertriglyceridemia; Elevated transaminases;

Prefixed ID : #118450;

Details


You can consult :


Nous contacter.
09/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.